围术期停用GLP-1受体激动剂两周对胃残留内容物的影响
单中心回顾性观察研究分析2023年8月至2025年5月择期胃镜患者,比较无GLP-1RA使用、继续使用及停药两周三组的胃残留内容物(RGC)发生率。继续使用GLP-1RA的RGC风险约为无使用者的十倍(OR 10.68),停药两周后风险降至与无使用统计学相当(OR 2.99,P=0.302),但肥胖患者即使停药两周风险仍高。
要点
- 继续使用GLP-1RA显著增加胃镜时胃残留内容物风险(OR 10.68)。
- 停药两周可使RGC风险降至与无使用统计学相当的水平。
- 肥胖(BMI≥28 kg/m2)患者即使停药两周RGC风险仍约为十倍。
核心结论
- 停药两周可降低GLP-1RA相关胃残留内容物发生率至与无使用相当的低水平,但对肥胖患者可能不足。
研究设计与样本
- 单中心回顾性观察研究,纳入2023年8月至2025年5月择期胃镜患者,按GLP-1RA暴露分为无使用、继续使用和停药两周三组。
主要发现
- RGC发生率:无GLP-1RA使用组0.4%(63/15902),继续使用组5.83%(6/103),停药两周组1.61%(1/62)。
- 继续使用GLP-1RA与RGC风险显著升高相关(OR 10.68,95%CI 3.74-30.55,p<0.001)。
- 停药两周组RGC风险与无使用组统计学可比(OR 2.99,95%CI 0.37-23.89,p=0.302)。
- 肥胖(BMI≥28 kg/m2)独立增加RGC风险,停药两周后风险仍约为无使用的十倍。
- 同期结肠镜检查对RGC有强保护作用,停药两周且同期结肠镜患者无RGC事件。
关键数值与推荐
- RGC定义为胃镜中见任何固体残留或>100 mL液体。
- 肥胖定义为BMI≥28 kg/m2。
临床怎么用
- 择期胃镜前可考虑停用GLP-1RA两周以降低RGC风险,正常体重或超重患者及同期结肠镜者尤为适用。
- 肥胖患者停药两周后仍需警惕RGC风险,应个体化评估。
局限性
- 单中心回顾性观察设计,GLP-1RA继续使用和停药两周组样本量小(分别为103例和62例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) slow gastric emptying and may therefore increase the risk of retained gastric contents (RGC). The optimal duration of discontinuation before esophagogastroduodenoscopy (EGD) under sedation or general anesthesia remains controversial. METHODS: We conducted a single-center, retrospective, observational study of patients who underwent elective EGD between August 2023 and May 2025. According to GLP-1RA exposure, patients were classified as (i) no GLP-1RA use, (ii) GLP-1RA continued use, or (iii) GLP-1RA two-week hold. The primary outcome was the presence of RGC, defined as any solid residue or > 100 mL of fluid visualized during EGD. Multivariate logistic regression was used to explore the relationship between GLP-1RA use and RGC. RESULTS: RGC occurred in 0.4% (63/15902) of patients with no GLP-1RA use, 5.83% (6/103) of patients with GLP-1RA continued use, and 1.61% (1/62) of patients with GLP-1RA two-week hold. GLP-1RA continued use was associated with a tenfold higher RGC risk versus no GLP-1RA use (odds ratio [OR] 10.68, 95% CI 3.74-30.55; p < 0.001), whereas a two-week hold reduced risk to a level statistically comparable with no GLP-1RA use (OR 2.99, 95% CI 0.37-23.89, p = 0.302). Obesity (BMI ≥ 28 kg/m2) independently increased RGC risk and, even after a two-week hold, yielded a tenfold higher risk of RGC versus no GLP-1RA use. Additionally, concurrent colonoscopy exerted a strong protective effect of RGC, and no RGC events occurred in patients with GLP-1RA two-week hold and concurrent colonoscopy. CONCLUSIONS: A two-week hold of GLP-1RA lowered RGC incidence to a low level comparable with no GLP-1RA use, especially in normal-weight or overweight patients and in those undergoing concurrent colonoscopy, but may be insufficient for obesity.
引用
- Dong Z, Li O, Wu J, et al. Effect of two-week perioperative glucagon-like peptide-1 receptor agonist interruption on retained gastric contents during esophagogastroduodenoscopy: a retrospective, observational study. Surg Endosc. 2026. PMID: 42426387. doi:10.1007/s00464-026-13121-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。